IL269879A - - Google Patents

Info

Publication number
IL269879A
IL269879A IL26987919A IL26987919A IL269879A IL 269879 A IL269879 A IL 269879A IL 26987919 A IL26987919 A IL 26987919A IL 26987919 A IL26987919 A IL 26987919A IL 269879 A IL269879 A IL 269879A
Authority
IL
Israel
Application number
IL26987919A
Other languages
English (en)
Other versions
IL269879B1 (en
IL269879B2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62067858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL269879(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of IL269879A publication Critical patent/IL269879A/en
Publication of IL269879B1 publication Critical patent/IL269879B1/en
Publication of IL269879B2 publication Critical patent/IL269879B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
IL269879A 2017-04-13 2018-04-09 Combination therapy for prostate cancer IL269879B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762485164P 2017-04-13 2017-04-13
PCT/US2018/026661 WO2018191141A1 (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer

Publications (3)

Publication Number Publication Date
IL269879A true IL269879A (https=) 2019-11-28
IL269879B1 IL269879B1 (en) 2025-06-01
IL269879B2 IL269879B2 (en) 2025-10-01

Family

ID=62067858

Family Applications (2)

Application Number Title Priority Date Filing Date
IL269879A IL269879B2 (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer
IL320452A IL320452A (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL320452A IL320452A (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer

Country Status (33)

Country Link
US (4) US20180296574A1 (https=)
EP (3) EP4176878A1 (https=)
JP (3) JP7141408B2 (https=)
KR (2) KR20260048358A (https=)
CN (2) CN110753545A (https=)
AU (2) AU2018251594A1 (https=)
CA (1) CA3059562A1 (https=)
CL (1) CL2019002871A1 (https=)
CO (1) CO2019011591A2 (https=)
CR (1) CR20190467A (https=)
DK (1) DK3609497T3 (https=)
DO (1) DOP2019000264A (https=)
EA (1) EA201992430A1 (https=)
ES (1) ES2931052T3 (https=)
HR (1) HRP20221327T1 (https=)
HU (1) HUE060460T2 (https=)
IL (2) IL269879B2 (https=)
JO (2) JOP20190244B1 (https=)
LT (1) LT3609497T (https=)
MA (1) MA48728B1 (https=)
MD (1) MD3609497T2 (https=)
MX (2) MX2019012296A (https=)
MY (1) MY209010A (https=)
NI (1) NI201900105A (https=)
PE (1) PE20200444A1 (https=)
PH (1) PH12019502317A1 (https=)
PL (1) PL3609497T3 (https=)
PT (1) PT3609497T (https=)
RS (1) RS63832B1 (https=)
SG (1) SG11201909552VA (https=)
SM (1) SMT202200467T1 (https=)
UA (1) UA129514C2 (https=)
WO (1) WO2018191141A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA124972C2 (uk) 2016-07-29 2021-12-22 Янссен Фармацевтика Нв Способи лікування раку передміхурової залози
WO2020139339A1 (en) * 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
CN110538150A (zh) 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
JP7442328B2 (ja) * 2020-02-03 2024-03-04 株式会社三共 遊技機
CN113546037B (zh) * 2020-04-20 2024-12-27 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
TWI905184B (zh) * 2020-05-08 2025-11-21 比利時商健生藥品公司 用醋酸阿比特龍和尼拉帕尼之組合治療前列腺癌
WO2022200982A1 (en) * 2021-03-24 2022-09-29 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
JP7320903B2 (ja) 2021-12-15 2023-08-04 湖南慧▲澤▼生物医▲薬▼科技有限公司 アビラテロン酢酸エステルを含む組成物及び使用
CN114306236B (zh) * 2021-12-15 2022-10-21 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
IL316019A (en) * 2022-04-07 2024-11-01 Astrazeneca Ab Combined treatment for cancer
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法
WO2025027138A1 (en) * 2023-08-02 2025-02-06 Janssen Pharmaceutica Nv Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
PL2478907T3 (pl) * 2006-08-25 2021-10-25 Janssen Oncology, Inc. Kompozycje do leczenia nowotworu
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
KR101653548B1 (ko) 2008-01-08 2016-09-02 머크 샤프 앤드 돔 리미티드 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2014089324A1 (en) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use

Also Published As

Publication number Publication date
EP3609497B1 (en) 2022-10-12
RS63832B1 (sr) 2023-01-31
KR20190134718A (ko) 2019-12-04
JP7407880B2 (ja) 2024-01-04
PL3609497T3 (pl) 2023-01-23
JP2022141881A (ja) 2022-09-29
MX2019012296A (es) 2019-11-28
PT3609497T (pt) 2023-01-23
MX2023009569A (es) 2023-08-22
JP2024023344A (ja) 2024-02-21
NI201900105A (es) 2020-03-11
US20240245710A1 (en) 2024-07-25
JOP20190244A1 (ar) 2019-10-13
UA129514C2 (uk) 2025-05-21
IL320452A (en) 2025-06-01
US20240398837A1 (en) 2024-12-05
PE20200444A1 (es) 2020-02-28
MD3609497T2 (ro) 2023-03-31
MA48728A (fr) 2020-04-08
MY209010A (en) 2025-06-16
CL2019002871A1 (es) 2019-12-27
CO2019011591A2 (es) 2020-02-28
EA201992430A1 (ru) 2020-02-28
JP2020516646A (ja) 2020-06-11
PH12019502317A1 (en) 2020-07-06
ES2931052T3 (es) 2022-12-23
WO2018191141A1 (en) 2018-10-18
CN110753545A (zh) 2020-02-04
SG11201909552VA (en) 2019-11-28
MA48728B1 (fr) 2022-10-31
HUE060460T2 (hu) 2023-03-28
JOP20230159A1 (ar) 2023-07-13
DK3609497T3 (da) 2022-10-31
AU2024202346A1 (en) 2024-05-02
AU2024202346B2 (en) 2026-01-22
US20220175801A1 (en) 2022-06-09
AU2018251594A1 (en) 2019-10-24
JP7141408B2 (ja) 2022-09-22
US20180296574A1 (en) 2018-10-18
CA3059562A1 (en) 2018-10-18
BR112019021466A2 (pt) 2020-05-12
CN119235874A (zh) 2025-01-03
CR20190467A (es) 2020-03-09
SMT202200467T1 (it) 2023-01-13
LT3609497T (lt) 2022-12-12
IL269879B1 (en) 2025-06-01
EP3609497A1 (en) 2020-02-19
EP4176878A1 (en) 2023-05-10
JOP20190244B1 (ar) 2024-04-18
DOP2019000264A (es) 2020-07-15
HRP20221327T1 (hr) 2023-03-17
IL269879B2 (en) 2025-10-01
KR20260048358A (ko) 2026-04-09
EP4176879A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
BR122021024397A2 (https=)
IL269879A (https=)
BR122021000189A2 (https=)
BR112019008823A2 (https=)
BR112020006084A8 (https=)
BR122022025811B8 (https=)
BR202018014992U2 (https=)
BR122021023687A2 (https=)
BR122021014832A2 (https=)
BR122022003518A2 (https=)
BR112020008820A2 (https=)
BR202017025154U2 (https=)
BR102017023327A2 (https=)
BR202017021228U2 (https=)
BR202017020981U2 (https=)
BR202017017068U2 (https=)
BR202017016984U2 (https=)
BR202017016924U2 (https=)
BR102017015495A2 (https=)
BR102017015250A2 (https=)
BR102017014430A2 (https=)
BR202017012548U2 (https=)
BR202017011220U2 (https=)
BR202017010814U2 (https=)
BR202017010373U2 (https=)